Weekly bortezomib + dexamethasone therapy for elderly patients with relapsed or refractory multiple myeloma (A multicenter clinical phase II trial, JMSG-0902) - Weekly bortezomib + dexamethasone therapy for elderly patients with relapsed or refractory multiple myeloma (JMSG-0902)

Japan myeloma study group0 个研究点目标入组 50 人开始时间: 2010年3月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Previous history of hypersensitivity for Bortezomib, dexamethasone, mannitol or boron 2) Non-secretary myeloma or plasma cell leukemia 3) Peripheral neuropathy (>=grade 2) 4) Positive for HIV antibody, HBs antigen, or HCV antibody. Patients with HTLV-1 antibody can be included. 5) Uncontrollable condition of liver dysfunction, renal dysfunction, heart failure, pulmonary failure, diabetes mellitus, hypertension, or infectious disease. 6) Active and progressive double cancer within 5 years (cured carcinoma in situ either the stomach, the large intestine, or the cervical uterus are excluded from double cancer). 7) Serious mental illness such as schizophrenia 8) Pregnant woman or possibility of getting pregnant, breast-feeding 9) Interstitial pneumonitis or lung fibrosis by the clinical findings, abnormal shadow of high-resolution chest CT, high levels of KL-6, SP-A, or SP-D 10) Others (inappropriate case)

发起方

Japan myeloma study group